Expert Answers to HCP Questions on CAR T-Cell Therapy

In this episode, Caron A. Jacobson, MD; Jae H. Park, MD; and Noopur Raje, MD, answer audience questions from a live CCO webinar focused on current best practices and emerging strategies in CAR T-cell therapy, with questions including:

• At what time in the treatment journey should CAR T-cell therapy be considered?
• How to select among 3 approved products for relapsed/refractory large B-cell lymphoma?
• How is CAR T-cell therapy best used for multiple myeloma?
• What qualities of bridging therapy are most preferred?
• When do patients receiving CAR T-cell therapy need COVID-19 or other vaccinations?  
• How are steroids optimally used in managing CAR T-cell therapy–related toxicities?

Presenters:

Caron A. Jacobson, MD
Assistant Professor
Division of Medical Oncology
Department of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Jae H. Park, MD
Associate Member  
Leukemia Service and Cellular Therapeutics Center  
Memorial Sloan Kettering Cancer Center
New York, New York

Noopur Raje, MD
Director
Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center  
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Content based on an online CME program supported by an educational grant from Bristol-Myers Squibb.

Link to full program:
https://bit.ly/3BfbEOf

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.